{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Taha TE"],"funding":["NIAID NIH HHS","U.S. Presidentâ€s Emergency Plan for AIDS Relief"],"pagination":["10-17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10840656"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["95(1)"],"pubmed_abstract":["<h4>Background</h4>Lifelong antiretroviral treatment (ART) use is recommended for pregnant and breastfeeding (BF) women living with HIV (WLWH) to prevent perinatal HIV transmission and improve maternal health. We address 2 objectives in this analysis: (1) determine timing and factors associated with BF cessation and (2) assess the impact of BF on health of WLWH on ART.<h4>Setting</h4>This multicountry study included 8 sites in Uganda, Malawi, Zimbabwe, and South Africa.<h4>Methods</h4>This was a prospective study of WLWH on lifelong ART. These women initially participated from 2011 to 2016 in a randomized clinical trial (PROMISE) to prevent perinatal HIV transmission and subsequently reenrolled in an observational study (PROMOTE, 2016-2021) to assess ART adherence, safety, and impact.<h4>Results</h4>The PROMOTE cohort included 1987 women on ART. Of them, 752 breastfed and were included in analyses of objective 1; all women were included in analyses of objective 2. The median time to BF cessation varied by country (11.2-19.7 months). Country of residence, age, and health status of women were significantly associated with time to BF cessation (compared with Zimbabwe: Malawi, adjusted hazard ratio [aHR] 0.50, 95% confidence interval [95% CI]: 0.40 to 0.62, P < 0.001; South Africa, aHR 1.49, 95% CI: 1.11 to 2.00, P = 0.008; and Uganda, aHR 1.77, 95% CI: 1.37 to 2.29, P < 0.001). Women who breastfed had lower risk of being \"unwell\" compared with women who never breastfed (adjusted rate ratio 0.87, 95% CI: 0.81 to 0.95 P = 0.030).<h4>Conclusion</h4>Women on lifelong ART should be encouraged to continue BF with no concern for their health. Time to BF cessation should be monitored for proper counseling in each country."],"journal":["Journal of acquired immune deficiency syndromes (1999)"],"pubmed_title":["Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa."],"pmcid":["PMC10840656"],"funding_grant_id":["UM1 AI069423","UM1 AI069469","UM1 AI069436","Multiple","UM1 AI069518","UM1 AI069530","U01 AI069436","UM1 AI069453"],"pubmed_authors":["Fowler MG","Chinula L","Gadama L","Bandala-Jacques A","Yende-Zuma N","Violari A","Atuhaire P","Brummel SS","Aizire J","Stranix-Chibanda L","Hanley S","Taha TE","Dadabhai S"],"additional_accession":[]},"is_claimable":false,"name":"Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa.","description":"<h4>Background</h4>Lifelong antiretroviral treatment (ART) use is recommended for pregnant and breastfeeding (BF) women living with HIV (WLWH) to prevent perinatal HIV transmission and improve maternal health. We address 2 objectives in this analysis: (1) determine timing and factors associated with BF cessation and (2) assess the impact of BF on health of WLWH on ART.<h4>Setting</h4>This multicountry study included 8 sites in Uganda, Malawi, Zimbabwe, and South Africa.<h4>Methods</h4>This was a prospective study of WLWH on lifelong ART. These women initially participated from 2011 to 2016 in a randomized clinical trial (PROMISE) to prevent perinatal HIV transmission and subsequently reenrolled in an observational study (PROMOTE, 2016-2021) to assess ART adherence, safety, and impact.<h4>Results</h4>The PROMOTE cohort included 1987 women on ART. Of them, 752 breastfed and were included in analyses of objective 1; all women were included in analyses of objective 2. The median time to BF cessation varied by country (11.2-19.7 months). Country of residence, age, and health status of women were significantly associated with time to BF cessation (compared with Zimbabwe: Malawi, adjusted hazard ratio [aHR] 0.50, 95% confidence interval [95% CI]: 0.40 to 0.62, P < 0.001; South Africa, aHR 1.49, 95% CI: 1.11 to 2.00, P = 0.008; and Uganda, aHR 1.77, 95% CI: 1.37 to 2.29, P < 0.001). Women who breastfed had lower risk of being \"unwell\" compared with women who never breastfed (adjusted rate ratio 0.87, 95% CI: 0.81 to 0.95 P = 0.030).<h4>Conclusion</h4>Women on lifelong ART should be encouraged to continue BF with no concern for their health. Time to BF cessation should be monitored for proper counseling in each country.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-06-01T05:23:33.517Z","creation":"2026-04-08T09:36:42.666Z"},"accession":"S-EPMC10840656","cross_references":{"pubmed":["37732877"],"doi":["10.1097/qai.0000000000003306","10.1097/QAI.0000000000003306"]}}